1. Home
  2. RPHM

as 06-13-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Founded: 2014 Country:
United States
United States
Employees: N/A City: IRVINE
Market Cap: 55.5M IPO Year: 2021
Target Price: $11.46 AVG Volume (30 days): 251.1K
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.18 EPS Growth: N/A
52 Week Low/High: $0.98 - $9.21 Next Earning Date: 08-08-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

RPHM Daily Stock ML Predictions

Stock Insider Trading Activity of Reneo Pharmaceuticals Inc. (RPHM)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Leonard Braden Michael RPHM 10% Owner May 14 '24 Buy $1.56 79,281 $123,678.36 2,337,194 SEC Form 4
Leonard Braden Michael RPHM 10% Owner May 14 '24 Buy $1.54 335,000 $515,900.00 2,672,194 SEC Form 4

Share on Social Networks: